Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › IPSC

Century Therapeutics

IPSC Rare disease Lead: Phase 1 3 Biotech Distilled articles ↓ 24 filings & releases ↓ Cash $49.6M (Jun 30, 2026) ↓ 3 verdicts ↓ 3 timing quotes ↓
ImmunologyMetabolicRenal Cell

Market cap $304M 181.1M shares (10-Q, Aug 3, 2026) × $1.68 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. CNTY-308 trial start2026CNTY-308 trial start, 2026, routine
  2. CNTY-813 IND filing4Q 2026CNTY-813 IND filing, 4Q 2026, material
  3. CNTY-813 topline2H 2027CNTY-813 topline, 2H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Technology platforms

Allo-Evasion

Proprietary iPSC engineering technology designed to enable allogeneic cell products to evade host immune recognition and rejection, enabling repeat dosing and persistence without chronic immunosuppression. Applicable to NK cell, T cell, and beta islet programs for autoimmune diseases and cancer.

Allo-Evasion 5.0

Immune-evasion engineering platform for iPSC-derived cell therapies; incorporates HLA-I deletion (b2M KO), HLA-II deletion (CIITA KO), pan-NK inhibitory ligand (CD300a TASR), and IgG-cleaving cell-surface enzyme to protect allogeneic grafts from T cell, NK cell, and humoral immune responses; applied to iPSC-derived islet cell therapies for Type 1 Diabetes

Targets: HLA-I, HLA-II, CD300a, b2M, CIITA

Capital (as filed)

Cash
$49.6M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$70.1M Jun 30, 2026
Long-term investments
$77.5M Jun 30, 2026
Operating cash flow
−$19.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$197M cash, runway 1Q 2029 per the update of Aug 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Century Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-31 Watch Century Therapeutics (IPSC) - Scientific Deep Dive for Allo-Evasion™ and Pipeline Products Strong pre-clinical science but no human proof-of-concept for Allo-Evasion 5.0; wait for CNTY-101 CARAMEL IST preliminary data before taking a meaningful position.
  2. 2026-06-08 Speculative buy speculative UPDATE: Century Therapeutics (IPSC) - The Humanized Mouse Passes the Test Humanized mouse data materially weakened the tumorigenicity and CMC pillars of the bear case, and locked GMP process de-risks manufacturing; a starter position is justified for risk-tolerant investors ahead of the CARAMEL IST and Q4 2026 IND.
  3. 2026-08-13 Speculative buy speculative UPDATE: Century Therapeutics (IPSC) - The FDA Said Yes to the Homework FDA pre-IND alignment on tox, manufacturing release testing, and Phase 1/2 design further weakens the regulatory and CMC pillars of the bear case while the stock drifts lower, but the core binary question of human immune evasion remains unanswered until 2027.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)